From the CoMMpass dataset higher S100A4 gene expression significantly correlated with lower PFS for MM patients who received carfilzomib-based therapy, suggesting S100A4 maybe a therapeutic target for MM patients. The gene discussed is S100A4; the disease is Miyoshi myopathy.